Brutalist Biotech
Max
3
|
5
|
10
|
20
items per feed.
Cutting-edge Biotech news: Presented the old-fashioned way.
Fierce Biotech
CMR Surgical kicks off Versius Plus robot’s US commercial launch
(1h)
Philips AI cath lab copilot nets FDA clearance
(3h)
Pulmatrix picked for reverse merger with anti-aging biotech weeks after Cullgen deal collapses
(3h)
OrbiMed-backed Pinnacle adds $89M series B to power oral peptide pipeline
(3h)
Wave crashes after obesity trial tracks 1% dip in body weight over 6 months
(4h)
Biopharma funding dropped 20% in 2025 as companies doubled down on big bets: IQVIA
(7h)
Innate ends work on NK cell engager in phase 1/2 trial as part of ongoing pipeline refocus
(8h)
FDA approves Denali's Hunter syndrome drug, breaking streak of rare disease rejections
(23h)
Scaling Radioligand Therapy: Expanding the Impact of Theranostics
(1d)
After ph. 2 readout, analysts herald 'best-in-class potential' for Maze kidney candidate as stock plummets
(1d)
BioPharma Dive
Merck’s deal for Terns sparks debate over a possible biotech bidding war
(1h)
FDA clears Denali drug in ‘clear step’ for rare disease biotechs
(2h)
Wave crashes on obesity drug update; Kodiak’s reboot pays dividends
(2h)
Maze tumbles on positive data for kidney disease drug
(22h)
Beam posts positive data on base editing treatment for AATD
(23h)
Sarepta sees early success with RNAi drugs from Arrowhead
(1d)
Merck to buy Terns in $6.7B bet on a ‘differentiated’ leukemia drug
(1d)
RA Capital targets China with latest SPAC deal
(2d)
Gilead, with Ouro deal, wagers $1.7B on bispecifics for autoimmune diseases
(2d)
Immutrin raises $87M to advance drug for progressive heart disease
(2d)
Endpoints News
Recordati says it's received a $12B+ takeover bid
(28m)
UCB picks Georgia for $2B biologics site; AbbVie exec visits China
(58m)
New tech, familiar problems
(1h)
Wave crashes on obesity disappointment
(2h)
Kodiak’s Phase 3 eye drug success; Innate discontinues anti-CD20 program
(3h)
Limbic aims to show AI beats humans in delivering therapy
(3h)
Post-Hoc: It’s time to make ACIP serious again
(3h)
Oral peptides biotech Pinnacle Medicines gets $89M from US, China investors
(6h)
FDA gives Denali accelerated approval for rare disease drug
(22h)
More changes ahead for Takeda with new CEO set to take reins
(22h)
BioSpace
Wave Stock Cut in Half on Underwhelming Higher Dose Obesity Data
(2h)
Beam’s Base Editor Advances to Pivotal Development on Back of ‘Impressive’ AATD Data
(5h)
Denali Delivers ‘Welcome Positive’ for Rare Disease Space With FDA's Hunter Syndrome Nod
(5h)
Sarepta Pushes Past Gene Therapy Debacle as RNA Therapies Show Early Promise
(5h)
Beyond Buzzwords in Longevity Investing
(8h)
Leadership, Not Managers, More Likely To Drive Employees Away, BioSpace Finds
(10h)
Beyond the Cornfields, Indiana’s Life Sciences Industry Grows Tall
(13h)
Maze Loses Nearly a Third of Market Share on Mixed Midstage Kidney Drug Data
(22h)
Maze Loses Nearly a Third of Market Cap on Mixed Midstage Kidney Drug Data
(22h)
Despite Novo's Robust Oral Wegovy Launch, Access Remains a Challenge for Obesity Drugs
(1d)
STAT News
Denali Therapeutics, Corcept Therapeutics win FDA approvals
(1h)
Health influencers talk social media and mental health
(1h)
A surprise opening for health care reforms
(2h)
White House misses deadline to nominate new CDC director
(3h)
Data show people racing to chatbots for health advice
(3h)
We’re reading about an FDA OK for a rare disease drug, a grilling of the PTO chief, and more
(4h)
Allogene’s off-the-shelf CAR-T is nearing an early but pivotal study readout
(7h)
Endometriosis is not just a gynecological disease
(9h)
The perimenopause movement sells women the lie that they are ruled by their hormones
(9h)
CDC leadership in limbo as Trump administration set to miss deadline to nominate director
(20h)
BioPharma Trend
Two Ex-GSK AI Leads Go Stealth with a New Oncology Drug Discovery Startup
(24m)
Tempus and Daiichi Sankyo Partner on AI-Guided Cancer Biomarker Discovery
(20h)
Bioptimus Launches Multimodal Tissue Atlas Across Three Continents
(1d)
Merck Signs $20M Deal With Quotient to Find IBD Targets Using Somatic Genomics
(2d)
insitro and Bristol Myers Squibb Add New AI-Found Targets in ALS Research
(2d)
Latent Labs Launches AI Agent for Antibody Design From a Single Text Prompt
(3d)
Earendil Labs Gets $787M to Push AI-Designed Antibodies Toward the Clinic
(3d)
AI-Guided Brain Implant for Memory Loss Gets FDA Breakthrough Status
(1w)
Dyno Launches Open-Source Agentic Protein Design Suite at GTC 2026
(1w)
AlphaFold Database Now Includes Protein Pair Interactions
(1w)
Drug Channels
Reflections and Photos from the Drug Channels Leadership Forum 2026
(1d)
NOW AVAILABLE: The 2026 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers
(2d)
Medical Benefit Maximizers Are Emerging as a Critical Market Force: What Manufacturers Need to Understand
(6d)
The Top 15 U.S. Pharmacies of 2025: Market Shares and Revenues at the Biggest Chains, PBMs, and Specialty Pharmacies
(1w)
Reshaping Patient Affordability: The Power of Expertise and Agility
(2w)
PBM Industry Update 2026: Trends, Challenges, and What’s Ahead (NEW Live Video Webinar)
(2w)
Time to Evolve: Hubs Flex to New Demands
(3w)
Preorder Now: DCI’s 2026 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers
(3w)
Beyond DTP 2.0: How Flexible Direct-to-Patient Programs Power Best-In-Class Patient Experiences
(4w)
Drug Channels News Roundup, February 2026: Mark Cuban on FTC-ESI, What Patients Really Want, QALYs vs. MFN, 340B’s Site of Care Shift, and New Faces at DCI
(1mo)
European Biotechnology Magazine
TenBoron lands €7.6m EU grant for precision radiotherapy trials in hard-to-treat cancers
(1h)
Immutrin secures £65m Series A for amyloid-removing heart therapy
(1d)
Organoids: new Roche research centre in Basel will focus on alternative model systems
(1d)
Sanofi inks up-to-$1.2bn autoimmune T-cell engager deal with Kali Therapeutics
(2d)
Mitigating regulatory risk with holistic CMC strategies
(2d)
Dutch biotech Laigo Bio bags €17m in oversubscribed seed round
(3d)
Leadership change
(3d)
Novartis strikes another billion-dollar oncology deal with acquisition of an early PI3Kalpha oral therapy
(6d)
Is the Unified Patent Court affordable for small biotechs?
(1w)
Recap AI Circular Economy Conference 2026
(1w)
Drug Hunter
February 2026 Patent Highlights
(2h)
ACS Spring 2026 First Time Disclosures
(18h)
TL1A Inhibition in IBD: Deamplifying Biology for Clinical Proof-of-Concept
(2d)
QPX7728
(3d)
Dose as the Ultimate MPO Endpoint
(5d)
imatinib
(6d)
Thermal Stability Assays as Tools to De-Risk Discovery
(1w)
valbenazine
(1w)
zalsupindole
(1w)
vipoglanstat (GS-248)
(1w)
Labiotech.EU
GSK’s two-speed strategy: broad sourcing and selective bets
(1d)
Seven T cell engager companies you should know about
(2d)
The six biotech companies in Portugal you should know about in 2026
(3d)
After the drought, biotech IPO activity begins to pick up in 2026
(6d)
How Leyden Labs is revolutionizing flu protection with its intranasal antibody spray
(6d)
Brain Awareness Week: could ongoing R&D spur neuroscience breakthroughs?
(1w)
Promising biotechs in Maryland right now
(1w)
Can Bristol Myers Squibb’s pipeline strategy offset a major patent cliff?
(1w)
Six biotech companies advancing the next generation of prostate cancer therapies
(1w)
How colorectal cancer treatment is evolving in 2026
(2w)
Bio IT World
The Value of Prediction, and Cost of Success, in Drug Hunting
(12h)
Follow the Money: Brain-Computer Retinal Implant, Expansion of Alzheimer’s Platform, Migraine Therapies
(1d)
Verily, Samsung Collaborate, Improving AI Trustworthiness, FDA Approval for PathAI
(2d)
PerturbAI Launches with CRISPR Atlas
(5d)
piRNAs Emerge as a New Frontier in Longevity
(1w)
Open Source ‘Floats All Boats’ in AI-Driven Drug Discovery
(1w)
Ancient Mushroom, Modern Medicine: Paul Stamets Says Agarikon Mycelium May Be Key to Fighting Viral Pandemics
(2w)
Russia to Expand National Genetics Database to Ensure Treatment for Various Ethnic Groups
(2w)
How HPC Systems Are Making Things Easier
(2w)
Infant Microbiome Atlas Makes Case for Region-Specific Probiotics
(3w)
GEN News
From Variability to Reliability: A New IgG4 Reference Standard for Consistent Characterization
(3h)
Georgia Chosen as the Location for UCB’s New U.S. Biologics Manufacturing Facility
(5h)
Merck Bolsters Cancer Pipeline with $6.7B Terns Buyout
(21h)
Leveraging the Full Potential of Regenerative Medicine Requires a Proactive Approach
(21h)
Parasites Prompt Gut-Brain Communication to Trigger Appetite Loss
(21h)
Epigenetic Memory from Inflammation May Prime the Gut for Colon Cancer
(21h)
The Three Pillars of Successful AI Deployments
(1d)
Biopharma Benefitting from AI in Manufacturing
(1d)
Scout-Triggered Proteomics Sharpens HCP Control
(1d)
Rentschler Highlights Milford Site Progress and Growth
(1d)
Cure Today
Treating Metastatic TNBC: Dr. Hope Rugo on ADCs and Personalized Therapy
(5d)
Understanding High-Risk Essential Thrombocythemia
(5d)
Son’s Decision to Donate Gave His Father a Second Chance
(5d)
Functional Precision Medicine Advances Brain Tumor Care
(5d)
Home-Based Chemotherapy at Mayo Clinic Shows Safe Option for Patients With Cancer
(6d)
Choosing Motherhood Amidst Stage 4 Breast Cancer
(6d)
FDA Approves Opdivo Combo for Newly Diagnosed Advanced Hodgkin Lymphoma
(6d)
How Honest Conversations Strengthened a Couple After Cancer
(6d)
Cardiac Health in Cancer Survivors: A Growing Need
(6d)
Why Open Communication is Crucial for Patients With Multiple Myeloma
(6d)
Contract Pharma
Lifecore Biomedical Inks Two New Agreements with Existing US Customer
(1h)
Piramal Pharma Solutions Procures Korsch X3 Tablet Press at Morpeth Facility
(21h)
Incyte Appoints Three to Executive Leadership Positions
(22h)
Sygnature Discovery Taps Susanne Back to Lead In Vivo Pharmacology Team
(1d)
Thermo Fisher Scientific Launches PPD CorEvitas Alzheimer’s Registry
(1d)
UCB to Build New U.S. Biologics Manufacturing Facility in Georgia
(1d)
Axplora Accelerates Growth with HPAPI Investments
(2d)
Quotient Therapeutics, Merck Partner on IBD Drug Targets
(2d)
Rentschler Biopharma Advances Milford Site Expansion
(2d)
Artis BioSolutions Establishes Synthetic DNA Mfg. Hub in Boston
(2d)
Pharma Times
Laigo Bio completes final close of €17m seed financing round
(7h)
Axplora announces expansion as newest part of $60m API investment programme
(1d)
DNA Script signs SYNTAX distribution agreements with Gencell, BMS and Biostream
(2d)
Ondine’s Steriwave phase 3 trial reaches 93% enrolment milestone
(3d)
Arvinas reports strong phase 1 results for ARV-102 in Parkinson’s disease
(1w)
Alzecure shares new preclinical data on NeuroRestore ACD856 at AD/PD conference
(1w)
Samsung Bioepis signs partnership with Sandoz for next‑generation biosimilars
(1w)
Atrogi begins dosing first subjects in human trial of ATR-258
(1w)
R1 Therapeutics launches with $77.5m to advance hyperphosphatemia treatment
(1w)
Taiwan Bio partners with Terumo to advance automated Treg manufacturing
(1w)
Medcity News
Frozen Does Not Mean Stable: Rethinking Cryopreservation in Cell and Gene Therapy Manufacturing
(3h)
DPC Is Scaling — The Financing Architecture Isn’t Ready
(3h)
Personalized Rehab Solution: Supporting Patients With Work Responsibilities
(4h)
Could There Be a ‘Soft Opening’ of H.R. 1 Medicaid Changes?
(15h)
Adonis Scores $40M for AI Platform Aiming to Boost Hospital Revenue
(16h)
Merck’s $6.7B Terns Acquisition Positions It to Challenge a Blockbuster Novartis Cancer Drug
(23h)
A New Opportunity to Reduce Resident Burnout: Young Doctors Are AI Natives
(1d)
Key Amenity Categories in Luxury Rehabs, According to The Sanctuary at Sedona
(1d)
The FDA Is Fast-Tracking Health AI —Women’s Health Can’t Be Left Behind
(1d)
Inside an Automated Healthcare Practice: Redesigning Care Around People, Not Paperwork
(1d)
Chemical & Engineering News
Supercapacitors built from bourbon waste
(1h)
Glyphosate could be boosting spread of multidrug-resistant bacteria
(3h)
How fish scales help reconstruct historical PFAS trends
(20h)
Surprisingly simple, sustainable lithium extraction
(22h)
Merck to buy Terns in $6.7 billion deal
(23h)
Progress toward a vaccine against oxycodone
(1d)
Editorial: The Iran war presents an energy reminder
(1d)
Lead-rich ash and dust traveled far afield of 2025 Los Angeles fires
(1d)
Women and early-career researchers hit hardest by NIH grant cancellations
(2d)
March 24 Business Watch: Helium capacity taken out in Qatar; Novartis to pay $2 billion for small molecule
(2d)
The Pharma Letter
Second positive Phase III results for Kodiak’s Zenkuda
(1h)
Late-stage pipeline to transform progressive pulmonary fibrosis treatment landscape
(1h)
Global R&D Trends 2026
(2h)
BRIEF—Lonza launches new development lab in Singapore
(2h)
Norgine wins Swissmedic approval of Pedmarqsi
(3h)
FDA orders warning for Parkinson’s mainstay after seizure cases
(3h)
FDA wastes no time in approving Corcept’s Lifyorli
(3h)
FDA warning letter stands out for stark images of plant conditions
(4h)
GC Biopharma wins first LatAm nod for Barycela
(4h)
Early-stage data allows Sarepta to bounce back
(5h)
Targeted Oncology
Ozekibart Plus Chemo Shows Promising Activity in R/R Ewing Sarcoma
(1w)
Reduced CRS Rates Support Wider Adoption of Bispecifics in Myeloma
(1w)
GLSI-100 Vaccine Shows <1% Annual Recurrence Rate in Phase 3 Breast Cancer Trial
(1w)
Treating Triple Negative Breast Cancer in the Frontline Setting
(1w)
Early Phase Evaluation of Intravesical Erdafitinib in NMIBC
(1w)
Zovegalisib Plus Fulvestrant Shows Durable PFS in PI3Kα-Mutated HR+/HER2− Metastatic Breast Cancer
(1w)
Phase 3 Trial of Eftilagimod Alfa in First-Line NSCLC Halted After Futility Analysis
(1w)
Keeping Bone Health Top of Mind in Androgen Deprivation Therapy
(1w)
Introducing CELMoDs into the Multiple Myeloma Treatment Paradigm
(1w)
Role of Dual Maintenance Remains Uncertain in Multiple Myeloma
(1w)
MedWatch
Novo Nordisk chairman: Cost-cutting was the most challenging decision in 2025
(2h)
Gubra re-elects board of directors
(3h)
Lundbeck Foundation reshuffles its board of directors
(3h)
Sweden bans Novo Nordisk's advertising for Wegovy following criticism
(4h)
BioPorto remains committed to reducing its operating deficit
(4h)
Lene Skole resigns as Lundbeck Foundation CEO
(5h)
Ahead of Novo's annual general meeting: Shareholders hope for more clarity regarding Rebien's chairmanship
(8h)
Pharma giants cut over 22,000 jobs amid looming patent cliff
(8h)
BioPorto maintains full-year guidance
(9h)
Novo Nordisk makes another price cut to Wegovy in South Africa
(9h)
In The Pipeline
Fentanyl's Membrane Behavior
(21h)
Set Phasers to "Kill". No, Not Those Phasers.
(1d)
AI-Predicting Compound Affinity. We Aren't There Yet.
(2d)
From Gut Bacteria Up to the Brain
(6d)
Beneficial Effects From the Liver to the Brain
(1w)
Now That's a Target-Guided Screen
(1w)
The Best Weapon Yet Against Sleeping Sickness
(1w)
Nitrogen, Ammonia, and the Strait of Hormuz
(2w)
In Cells and Outside of Them
(2w)
A Unique Situation for UniQure
(2w)
Pharmaphorum
Wave's stock wavers on obesity drug data
(12m)
AI predicts liver cancer risk with "high accuracy"
(5h)
Corcept gets FDA OK for first-in-class ovarian cancer drug
(6h)
FDA clears Denali's 'game-changer' Hunter syndrome drug
(7h)
Anavex sinks after pulling Alzheimer's filing in EU
(22h)
ImmunityBio warned by FDA over 'misleading' Anktiva content
(1d)
Grifols board backs IPO for US business
(1d)
Patient sues Novartis, claiming data-tracking privacy breach
(1d)
Novo unveils first data for 'triple G' agonist in diabetes
(1d)
AI in drug discovery and development: news watch
(1d)
Drug Discovery Weekly
Global collaboration aims to create safer cancer therapeutics
(2h)
DDW Highlights: 26 March 2026
(5h)
Obesity could be treated without suppressing appetite
(6h)
Whitepaper: Secure your place in the IND race
(7h)
Just – Evotec Biologics enters $10m agreement with BARDA
(8h)
New protein drugs could pave way for faster drug development
(1d)
Gilead to advance first T cell engager for autoimmune diseases
(1d)
‘Supercharged’ T cells could improve prostate cancer treatment
(1d)
Twelve startups to showcase at SLAS Europe 2026
(1d)
Lilly’s triple agonist significantly reduces A1C and weight
(1d)
HIT Consultant
Beyond the AI Arms Race: Why Collaborative Intelligence Is the Only Path Forward for Utilization Management
(1d)
The RCM Trap: Why Cityblock Health is Pivoting AI Investment Toward Medicaid Care
(1d)
The C-Suite Squeeze: Why Hospital IT Budgets Are Shrinking While AI Spending Soars
(2d)
Hopper OS Acquires Healthcare Informatics Company Efferent to Expand Cloud PACS and Interoperability
(2d)
TruBridge and Artesia General Hospital Integrate Microsoft Dragon Copilot into EHR
(2d)
Cerebral Acquires Cognitive Behavioral Therapy App Inflow to Expand ADHD Treatment
(2d)
ImmuneBridge Secures $7.7M to Open Cell Therapy Manufacturing Platform to Biotech Partners
(2d)
Zocdoc Report: 26% of Patients Now Use AI for Medical Advice, Creating a ‘Triangle of Care’
(2d)
Viz.ai and Alnylam Pharmaceuticals Partner to Launch AI Care Pathway for Cardiac Amyloidosis
(2d)
AI Didn’t Fix HCC Coding—It Made It Harder. This is How to Fix It
(2d)
Insights: Pink Sheet
Quotable: Top Experts On Policy Hot Topics
(2h)
Iran War: Fuel Woes Exacerbate Fragility Of Europe’s Medicines Distribution System
(4h)
India Tightens Oversight Of GLP-1 Supply Chain Amid Concerns Of ‘On-Demand’ Availability
(8h)
Denali’s Avlayah Offers Broader Treatment Of Hunter Syndrome, Evidence Of US FDA Flexibility
(18h)
US FDA Allergenics Staff Sees Single-Trial ‘Default’ As Helpful
(20h)
GDUFA IV: US FDA Worries About Revenue Shortfalls, Industry Does Not
(22h)
Speak To Multiple Regulators, Orchard Advises, Drawing On US Lenmeldy Challenges
(1d)
Regulatory Departments Must Prepare For The Digital-First Era In Europe
(1d)
Neurology Treatments From Scholar Rock & Sanofi Among Drugs Up For EMA Oral Explanations
(1d)
Korean Ministries Collaborate To Foster Bioventures, Blockbusters
(1d)
BioXconomy
How the Digital Medicine Society is advancing clinical trials with digital innovation
(3h)
DiMe CEO on how digital medicine is set to redefine clinical trials
(3h)
Merck bolsters oncology portfolio with $6.7bn acquisition of Terns
(5h)
PhaseV debuts AI offering to automate clinical trials
(22h)
Pfizer’s trispecific antibody shows promise in treating eczema
(1d)
‘Expect the unexpected’: Navigating biotech M&A in an unpredictable climate
(1d)
SEC leaders prioritize reducing regulatory burdens, streamlining disclosure rules for companies
(1d)
Peptide conjugates loosen up antibody therapeutics for range of conditions
(1d)
UK government to examine how AI can optimize trials
(2d)
Gilead’s $2.2bn buy of Ouro Medicines includes Galapagos alliance
(2d)
BioCentury
Science Spotlight: AI studies link preserved thymic function to longer life
(17h)
With $6.7B buy, Merck sees ‘best-in-class’ blockbuster in Terns’ CML therapy
(17h)
Denali approval revives surrogate-endpoint path in neuronal MPS
(17h)
MHRA’s Tallon on the tall order of boosting the U.K. as a destination for clinical trials
(19h)
AL-S Pharma tests how far SOD1 biology extends into sporadic ALS
(1d)
Gilead seeks to defend HIV, reset I&I and bolster oncology
(1d)
Gilead seeks to put Galapagos’ cash to work as it buys bispecifics developer Ouro
(1d)
Arrowhead’s arc. Plus: AI in biotech venture, Synnovation, MFN
(2d)
Apogee makes long-interval dosing case in atopic dermatitis, Valneva falls on Lyme disease data, and more
(2d)
J&J’s posdinemab data sharpen questions around tau biomarkers in Alzheimer’s
(2d)
SCRIP
How The Kelun-Merck Pact Shaped Future Of China Dealmaking
(50m)
Anavex Not Giving Up On Alzheimer’s Drug After EU Rejection
(3h)
Executives On The Move: Alphamab Oncology Gets A New CFO From AstraZeneca
(6h)
Biogen Added To Alteogen’s Long List Of Partners
(12h)
Denali’s Avlayah Offers Broader Treatment Of Hunter Syndrome
(19h)
US FDA Approves Corcept’s Lifyorli For A Broad Ovarian Cancer Population
(20h)
Merck’s Case For Terns: Blockbuster Potential For TERN-701, Room For More Deals
(20h)
Beam To Extend Current Trial For Pivotal BEAM-302 Development
(21h)
Spring In The Step Is Back For Neuroscience Biotechs
(1d)
Novo And United’s Triple-G Agonist Scores In Diabetes Study
(1d)